(Q48666094)

English

Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.

scientific article published on 19 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Laura J. Havrilesky

1

object named as

Laura J Havrilesky

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Angeles Alvarez Secord

9

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

8

object named as

Evan R Myers

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Andrew Berchuck

7

object named as

Andrew Berchuck

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Lawrence R Nycum

5

object named as

Lawrence R Nycum

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Robin M Pokrzywinski

2

object named as

Robin Pokrzywinski

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Dennis A Revicki

3

object named as

Dennis Revicki

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

author name string

Robert V Higgins

4

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Matthew F Kohler

6

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

language of work or name

0 references

publication date

19 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

118

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

2

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

386-391

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Management of platinum-sensitive recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26199

21 January 2018

Identifiers

10.1002/CNCR.26199

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21598242

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48666094&oldid=1739980098"